Regulatory Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approval Pharmaceutical TechnologyLantheus's radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology.NeuroscienceRead full story pharminent August 17, 2026 (Last updated: August 18, 2026) Pharmaceutical Technology Lantheus’s radiodiagnostic is designed to identify cognitively impaired patients who have tau neurofibrillary tangle (NFT) pathology. Neuroscience Read full story Post navigation Previous: BMS Wins First FDA Approval for CELMoD Class With Zenbexus in Multiple MyelomaNext: Sandoz targets industry patent void with $322m Henlius deal Related Stories Regulatory UK regulators greenlight Lilly’s Foundayo, intensifying Novo competition pharminent August 11, 2026 Regulatory Replimune rebounds to win FDA approval of melanoma drug pharminent August 6, 2026 Regulatory Takeda’s first-in-class narcolepsy drug claims FDA approval pharminent August 6, 2026
